Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Roden, Michael, Weng, Jianping, Eilbracht, Jens, Delafont, Bruno, Kim, Gabriel, Woerle, Hans J, Broedl, Uli CVolume:
1
Language:
english
Journal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(13)70084-6
Date:
November, 2013
File:
PDF, 375 KB
english, 2013